Search
forLearn
5 / 801 resultslearn copper tripeptide-1
learn HT-B
learn Tricopper peptides
learn AHK-Cu Copper Tripeptide
Research
5 / 101 results
research Hair Follicle Signaling Networks: A Dermal Papilla–Centric Approach
The document concludes that dermal papilla cells are key for hair growth and could be used in new hair loss treatments.
research A matter of life and death: self‐renewal in stem cells
Stem cell self-renewal is complex and needs more research for full understanding.
research Genome-wide association study in Japanese females identifies fifteen novel skin-related trait associations
Researchers found 15 new genetic links to skin traits in Japanese women.
research Characterisation of CD4+ stem cells of the skin and their role in skin homeostasis and tumourigenesis
CD4+ skin cells may be precursors to basal cell carcinoma.
research Discovering New Progenitor Cell Populations through Lineage Tracing and In Vivo Imaging
New methods have helped find cells that create other cells in the body.
Community Join
5 / 1000+ resultscommunity When will Breezula be released and how does it compare to KX-826?
Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.
community Breezula or kx-826 which one is better ?
Breezula (cb-03-01) and kx-826 are discussed as hair loss treatments. Kx-826 is available on Kintor's website, while Breezula is available on the grey market.
community TGF-Beta. Good or Bad? Help for treatment investment
TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.
community Selling KY19382 powder a novel activator of Wnt/β-catenin signaling Product
Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.
community Kintor KX -826 Pyrilutamide Adds 1 Year Phase 3 Trial For Safety
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.